Why universities should step up in venture investing

Nature Biotechnology

Volumn 30, Issue 10, 2012, Pages 933-936

  Christini, Amanda ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DRUG INDUSTRY; INVESTMENT; NOTE; PRIORITY JOURNAL; RESEARCH; TECHNOLOGY; UNITED STATES; UNIVERSITY;

BIOTECHNOLOGY; CAPITAL FINANCING; DRUG INDUSTRY; INVESTMENTS; NATIONAL INSTITUTES OF HEALTH (U.S.); THERAPIES, INVESTIGATIONAL; UNITED STATES; UNIVERSITIES;

EID: 84867361156     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2390     Document Type: Note

References (5)

1. Kneller, R. Nat Rev. Drug Discov. 9, 867-882 (2010)
2. National Venture Capital Association. Venture capital firms raise $5.6B in fourth quarter 2011 as indus-try continues to consolidate (Thomson Reuters news release, 9 January 2012).
3. National Venture Capital Association. Venture capital investments experience double-digit increases in dol-lars and deal volume in Q2 2012: internet-specific and early stage investing jumps; life sciences investing falls (Thomson Reuters news release, 20 July 2012).
4. Booth, B.L. Nat Biotechnol. 27, 705-709 (2009).
5. Booth, B.L. & Salehizadeh, B. Nat Biotechnol. 29, 579-583 (2011).